Trial
MMPOWER-3
Research Observatory
Evidence Update
Current evidence
MMPOWER-3 compared elamipretide with placebo in people with primary mitochondrial myopathy. It did not meet either prespecified primary endpoint—six-minute walk distance or total fatigue score—at 24 weeks in the overall study population.
What changed
The governed evidence now includes the exact 2024 genotype-specific publication as a separate work reporting post-hoc analyses of the same MMPOWER-3 trial. It adds exploratory six-minute-walk observations for genetically and phenotypically defined subgroups, with complete source and release provenance.
What did not change
The Phase 3 conclusion remains negative at the whole-cohort level. The 2024 paper is not an independent replication, does not establish overall elamipretide efficacy, and supersedes no accepted assertion.
Why it matters
The subgroup pattern makes a more specific research question possible: could prospectively selected patients with relevant nuclear-gene replisome variants, potentially combined with the CPEO phenotype, respond differently? That is useful for designing a future test, not for claiming the treatment already works.
Main limitation
These are post-hoc findings from small subgroups in a heterogeneous disease. Six-minute walk was the only outcome with a strong differential subgroup effect; fatigue and other endpoints did not provide comparable confirmation, and generalizability remains unresolved.
Next proof
A prospectively designed, adequately powered study should predefine the responsive genotype or phenotype and use validated functional and patient-relevant endpoints. That evidence—not retrospective subgroup significance—would materially change confidence.
Summary
MMPOWER-3 did not meet either prespecified primary endpoint—six-minute walk distance or total fatigue score—at 24 weeks in the overall study population.
Intelligence Take
The subgroup pattern makes a more specific research question possible: could prospectively selected patients with relevant nuclear-gene replisome variants, potentially combined with the CPEO phenotype, respond differently? That is useful for designing a future test, not for claiming the treatment already works.
Limitations
These are post-hoc findings from small subgroups in a heterogeneous disease. Six-minute walk was the only outcome with a strong differential subgroup effect; fatigue and other endpoints did not provide comparable confirmation, and generalizability remains unresolved.